Eddingpharm announces an exclusive agreement with Lilly China for the promotion and distribution of Ceclor® and Vancocin® in China

Eddingpharm has entered into an agreement with Lilly China, whereby Eddingpharm will hold the exclusive rights to promote and distribute Lilly’s Ceclor® and Vancocin® antibiotic products in mainland China beginning on 1 January 2017.

Under the terms of the agreement, the two drugs will continue to be marketed as Lilly Ceclor® and Lilly Vancocin® and Lilly will continue to manufacture both antibiotic products in accordance with its global product quality standards.

Xin Ni, CEO of Eddingpharm, said: “We are excited to partner with Lilly and we are very proud to continue providing patients with two of Lilly’s high quality antibiotics. With more than 10 years of operational experience, Eddingpharm has already established strict compliance processes and highly efficient management systems. These systems and track record represent a powerful guarantee of our ability to increase availability of medicines produced by multinational companies. This strategic partnership also enhances Eddingpharm’s core competitiveness. We will leverage our national network and significant expertise in distributing specialty drugs to provide a broader range of channels for these two drugs, reach more Chinese patients, and maintain strong patient support.”

Andrew Hodge, President of Lilly China, said: “We are pleased to establish this partnership with Eddingpharm. Through their extensive network, we are confident that these trusted and highly effective medicines will reach even more patients across China. Importantly, this strategic partnership will also enable Lilly to focus resources on developing our extensive portfolio and pipeline of innovative, life-changing medicines. Over the next decade, we ARE planning to introduce 10 new drugs to the China market that will help even more patients live longer, healthier, And more active lives.”

As one of the best-selling antibiotics in the world, Ceclor® entered China IN 1993, And became a highly trusted brand of oral antibiotics among China’s physicians. Vancocin®, which entered China IN 1996, has become the gold STANDARD IN treating MRSA (methicillin-resistant Staphylococcus aureus) due to its high degree of efficacy and excellent patient SAFETY record. over the past two decades, Ceclor® and Vancocin® have helped nearly 10 million Chinese patients.

Unit 122-129, Building A3 No.700, Wanrong Road,Shanghai



Copyright © 2019 亿腾医药 版权所有

药监局备案号: (沪) -非经营性-2021-0038